Management and immediate outcome of patients with intracoronary thrombus during percutaneous transluminal coronary angioplasty
- PMID: 1615790
- DOI: 10.1016/0002-8703(92)90912-f
Management and immediate outcome of patients with intracoronary thrombus during percutaneous transluminal coronary angioplasty
Abstract
A retrospective analysis of our experience with intraprocedural thrombus complicating percutaneous transluminal coronary angioplasty (PTCA) was undertaken. Of 983 PTCA procedures reviewed, 62 (6.3%) were complicated by thrombus. Patients were managed conservatively (group I, n = 18), with redilation (group II, n = 17), or with intracoronary urokinase and redilation (group III, n = 27). The three groups did not differ with respect to demographic or baseline angiographic variables, but complications, defined as death, myocardial infarction, bypass surgery, or threatened occlusion requiring emergency stenting, occurred in 11% of patients in group I, 24% in group II, and 48% in group III. Occlusive thrombus behavior was observed in 80% of these 62 patients. Patients with complications were less likely to have received antecedent antiplatelet therapy (79% vs 95% of patients without complications), had more complex baseline lesion morphology, more often had thrombus present at baseline (42% vs 19%), and more often had a low activated clotting time at the start of PTCA (53% vs 8%). Thrombi that led to complications more frequently exhibited occlusive behavior before therapy was begun (95% vs 71%) and more often occurred in the setting of intimal dissection (42% vs 14%). Patients undergoing PTCA at the time of diagnostic catheterization were more likely to have complications than those in whom PTCA was delayed. A successful outcome was more likely (83% vs 27%, p = 0.03) in group III if at least 140,000 U of urokinase were administered within 50 minutes of the appearance of thrombus. Thus intracoronary thrombus formation during PTCA remains a significant source of morbidity.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Intracoronary urokinase as an adjunct to percutaneous transluminal coronary angioplasty in patients with complex coronary narrowings or angioplasty-induced complications.Am J Cardiol. 1992 Jan 1;69(1):57-62. doi: 10.1016/0002-9149(92)90676-p. Am J Cardiol. 1992. PMID: 1729868
-
Angiographic evolution of intracoronary thrombus and dissection following percutaneous transluminal coronary angioplasty (the Thrombolysis and Angioplasty in Unstable Angina [TAUSA] trial).Am J Cardiol. 1997 Mar 1;79(5):559-63. doi: 10.1016/s0002-9149(96)00815-6. Am J Cardiol. 1997. PMID: 9068508 Clinical Trial.
-
Intracoronary urokinase for intracoronary thrombus accumulation complicating percutaneous transluminal coronary angioplasty in acute ischemic syndromes.Circulation. 1990 Dec;82(6):2052-60. doi: 10.1161/01.cir.82.6.2052. Circulation. 1990. PMID: 2242529
-
Management of intracoronary thrombosis complicating percutaneous transluminal coronary angioplasty.Clin Cardiol. 1996 Jul;19(7):536-42. doi: 10.1002/clc.4960190704. Clin Cardiol. 1996. PMID: 8818433 Review.
-
The emergence of mechanical thrombectomy; a clot burden reduction approach.Semin Interv Cardiol. 2000 Sep;5(3):137-47. Semin Interv Cardiol. 2000. PMID: 11054911 Review.
Cited by
-
A guide to drug use during percutaneous coronary intervention.Drugs. 2002;62(18):2589-601. doi: 10.2165/00003495-200262180-00003. Drugs. 2002. PMID: 12465999 Review.
-
Use of the activated clotting time in anticoagulation monitoring of intravascular procedures.Tex Heart Inst J. 1993;20(4):258-63. Tex Heart Inst J. 1993. PMID: 8298321 Free PMC article. Review.
-
Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention.Curr Control Trials Cardiovasc Med. 2001;2(3):129-140. doi: 10.1186/cvm-2-3-129. Curr Control Trials Cardiovasc Med. 2001. PMID: 11806786 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources